Cargando…

Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments

BACKGROUND: Peripheral blood-based biomarkers (PBB) predicting response, survival and immune-related adverse events (irAEs) in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are still a matter of debate. Thus, we investigated the associatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yuequan, Liu, Xiaoyan, Liu, Jia, Zhang, Dongming, Liu, Xiangning, Yue, Yuan, Zhou, Qing, Gao, Xiaoxing, Chen, Minjiang, Xu, Yan, Zhao, Jing, Zhong, Wei, Provencio, Mariano, Jassem, Jacek, Williams, Terence M., Seeber, Andreas, Kocher, Florian, Wang, Mengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743518/ https://www.ncbi.nlm.nih.gov/pubmed/35070755 http://dx.doi.org/10.21037/tlcr-21-710

Ejemplares similares

Circulating cytokines associated with clinical outcomes in advanced non‐small cell lung cancer patients who received chemoimmunotherapy
por: Shi, Yuequan, et al.
Publicado: (2021)

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
por: Zhang, Dongming, et al.
Publicado: (2022)

Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023)

Risk factors for immune-related adverse events: what have we learned and what lies ahead?
por: Liu, Xiaoyan, et al.
Publicado: (2021)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
por: Liu, Jia, et al.
Publicado: (2022)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Clinicopathological characteristics of lung cancer in patients with systemic sclerosis
por: Chen, Minjiang, et al.
Publicado: (2020)

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy
por: Liu, Jia, et al.
Publicado: (2023)

Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor‐associated myocarditis
por: Xu, Yan, et al.
Publicado: (2022)

Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?
por: Liu, Xiaoyan, et al.
Publicado: (2017)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
por: Zhao, Jing, et al.
Publicado: (2023)

Sarcoidosis‐like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response
por: Shi, Yuequan, et al.
Publicado: (2021)

Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
por: Chen, Minjiang, et al.
Publicado: (2021)

Afatinib as first‐line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature
por: Shi, Yuequan, et al.
Publicado: (2018)

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer
por: Liang, Hongge, et al.
Publicado: (2022)

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
por: Liang, Hongge, et al.
Publicado: (2018)

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China
por: Shi, Yuequan, et al.
Publicado: (2021)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer
por: Xu, Yan, et al.
Publicado: (2020)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist
por: Yang, Yongjie, et al.
Publicado: (2021)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

Immunotherapy as second‐line treatment and beyond for non‐small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real‐world retrospective analysis
por: Chen, Minjiang, et al.
Publicado: (2020)

Neoadjuvant immunotherapy followed by surgery with curative intent in 35 patients with advanced NSCLC: the retrospective experiences of a multidisciplinary team
por: Ma, Dongjie, et al.
Publicado: (2022)

Multi‐organs perioperative immune‐related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC
por: Xu, Yuan, et al.
Publicado: (2022)

Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
por: Xu, Yuan, et al.
Publicado: (2023)

Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
por: Chen, Minjiang, et al.
Publicado: (2023)

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2021)

Opportunistic infections complicating immunotherapy for non‐small cell lung cancer
por: Liu, Ziwei, et al.
Publicado: (2020)

High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)
por: Kocher, Florian, et al.
Publicado: (2021)

Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives
por: Zimmer, Kai, et al.
Publicado: (2021)

ALK‐rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report
por: Xu, Yan, et al.
Publicado: (2018)

Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death
por: Chen, Minjiang, et al.
Publicado: (2015)

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period
por: Ni, Jun, et al.
Publicado: (2021)

The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor
por: Amin, Saber, et al.
Publicado: (2020)

Case Series of Acute Peripheral Neuropathies in Individuals Who Received COVID-19 Vaccination
por: Sukockienė, Eglė, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nn4f136roonb6q8fifnrttgocn